YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H (HK:1558) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. has entered a licensing agreement with Shenyang Sunshine Pharmaceutical Co., Ltd. to commercialize Clifutinib Besylate in China. The agreement involves an upfront payment of RMB 60 million, with additional milestone payments contingent on certain achievements. This strategic move aims to leverage Clifutinib’s potential in the Chinese market, while the company retains rights outside of China.
For further insights into HK:1558 stock, check out TipRanks’ Stock Analysis page.